https://vitalspanwire.com/news/avexitide-phase-3-post-bariatric-hypoglycemiaVitalspan Wireen2026-08-22T21:02:15.458ZAvexitide reduced severe hypoglycemia after gastric bypass in Phase 3 trialhttps://vitalspanwire.com/news/fda-aletta-robotic-blood-draw-authorizationVitalspan Wireen2026-08-22T16:01:52.993ZFDA authorizes first standalone robotic blood-draw devicehttps://vitalspanwire.com/news/preclinical-obesity-five-year-progressionVitalspan Wireen2026-08-22T11:02:35.288ZOne in three adults with ‘preclinical obesity’ progressed within five yearshttps://vitalspanwire.com/news/pt00114-fda-pre-ind-anxiety-trialVitalspan Wireen2026-08-21T21:02:01.678ZProtagenic outlines U.S. trial path for neuropeptide PT00114 after FDA feedbackhttps://vitalspanwire.com/news/epigenetic-clocks-longevity-interventions-translageVitalspan Wireen2026-08-21T16:02:20.087ZLarge human-study analysis tests which epigenetic clocks respond to longevity interventionshttps://vitalspanwire.com/news/bmal1-yap-aged-skin-inflammation-miceVitalspan Wireen2026-08-21T11:01:58.514ZAging redirects two skin regulators toward inflammatory genes in mice